Study on the effect of neoadjuvant chemotherapy combined with intermittent tumor cell reduction surgery in the treatment of ovarian cancer
新辅助化疗联合间歇性肿瘤细胞减灭术治疗卵巢癌的效果研究

摘要

目的 探究在卵巢癌患者的临床治疗中采用新辅助化疗（NACT）联合间歇性肿瘤细胞减灭术（IDS）的实际价值；方法 采用前瞻性研究的手段，以2021年1月-2024年7月为研究时段，选取该时段我院收治的60例晚期卵巢癌患者，以治疗方案作为分组标准，观察组与对照组各30例。对照组选用初始肿瘤细胞减灭术（PDS）联合术后辅助化疗；观察组采用NACT联合IDS；结果 观察组在临床治疗效果及各项临床指标上均具有一定优势（P<0.05）；结论 对卵巢癌选用NACT联合IDS的治疗手段，相较于PDS联合术后辅助化疗的效果更显著，能够有效提升临床治疗效果，减少术中出血量，促进术后更快恢复，应用价值良好。

Abstract

Objective To explore the practical value of using neoadjuvant chemotherapy (NACT) combined with intermittent tumor cell depletion (IDS) in the clinical treatment of ovarian cancer patients;
Methods A prospective study was conducted from January 2021 to July 2024, selecting 60 patients with advanced ovarian cancer admitted to our hospital during this period. The treatment plan was used as the grouping criterion, with 30 patients in the observation group and 30 patients in the control group. The control group received initial tumor cell reduction surgery (PDS) combined with postoperative adjuvant chemotherapy; The observation group used NACT combined with IDS;
Results The observation group had certain advantages in clinical treatment efficacy and various clinical indicators (P<0.05);
Conclusion   The use of NACT combined with IDS for the treatment of ovarian cancer has a more significant effect compared to PDS combined with postoperative adjuvant chemotherapy. It can effectively improve clinical treatment efficacy, reduce intraoperative bleeding, promote faster postoperative recovery, and has good application value.